News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK) Sales Rise Ahead of Anticipated Drug Approval


10/17/2013 6:58:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion, Europe's largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week. Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs ($1.24 billion). Net profit was 105 million francs in the third quarter, beating analysts' forecasts of 88.5 million.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters

comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES